← Back to Search

Proteasome Inhibitor

Participants With Multiple Myeloma (MM) for Multiple Myeloma

N/A
Recruiting
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group

Summary

The main aim of this study is to check side effects and results in adults with multiple myeloma after switching from a bortezomib/carfilzomib -based to an Ixazomib-based treatment.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression Free Survival (PFS) at 24 Months
Secondary study objectives
Duration of CR
Duration of Ixazomib Therapy (DOT)
HRQOL Based on EORTC QLQ-C30
+9 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants With Multiple Myeloma (MM)Experimental Treatment1 Intervention
Participants diagnosed with MM (newly diagnosed multiple myeloma \[NDMM\] and first relapse multiple myeloma \[FRMM\]) using International Myeloma Working Group (IMWG) criteria who received a bortezomib/carfilzomib-based triple-drug regimens for more than 2 cycles as initial therapy, achieved at least partial response (PR) as defined by IMWG criteria, and are ready to start receiving an ixazomib containing therapy prescribed by their treating physician will be observed prospectively for 24 months.

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,234 Previous Clinical Trials
4,147,832 Total Patients Enrolled
50 Trials studying Multiple Myeloma
15,303 Patients Enrolled for Multiple Myeloma
Study DirectorStudy DirectorTakeda
1,270 Previous Clinical Trials
503,780 Total Patients Enrolled
25 Trials studying Multiple Myeloma
4,600 Patients Enrolled for Multiple Myeloma
~75 spots leftby Jun 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top